According to its developers, the cream features a unique drug that has shown promise for inhibiting skin cancer formation and also for treating early-stage conditions in organ transplant patients who are given immunosuppressive medications in a bid to prevent organ rejection.

Although life-saving, immunosuppressive medications tend to elevate the risk of developing certain skin cancers dramatically — specifically squamous cell carcinomas (SCC) and Kaposi’s Sarcoma.

The team explained that the drug was discovered and developed in collaboration with the university's commercialization company UniQuest and its small molecule drug discovery initiative, QEDDI.

Currently in the pre-clinical development phase, the topical cream is being assessed for its effectiveness in penetrating the skin and the team is exploring the possibilities for large-scale manufacturing in the future.

This process will reportedly ensure that when the time comes for human trials, the topical cream will have undergone rigorous testing to verify its safety and efficacy.